Drugs / Antaitavir Hasophate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05446233 | Nov 2022 → Jan 2023 | — | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Antaitavir Hasophate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05446233 ↗ |
| Route | Oral | “a single oral dose” NCT05446233 ↗ |